Ocular Therapeutix reports results and business highlights – TradingView News in the first quarter of 2025

Ocular Therapeutix, Inc., a biopharmaceutical company that focuses on innovative treatments for retinal diseases, has published its financial results for the first quarter of March 31, 2025. The company has made considerable progress in its clinical studies and maintains a strong financial position.

Financial highlights

In the first quarter of 2025, Ocular Therapeutix recorded a total net sales of $ 10.7 million, which was primarily due to a decline of 27.6% compared to the $ 14.8 million in 2024 in the same period of 2024 to reduced gross income from the turnover of Dextenza. The net loss for the quarter in the first quarter of 2024 was a net loss of $ 64.1 million or ($ 0.38) per share compared to a net loss of $ 64.8 million or ($ 0.49) per share.

The research and development costs increased significantly from USD 20.7 million in the previous year to $ 42.9 million, which is due to higher clinical expenses for the SOL-1 and SOL-R phase 3 studies. Sales and marketing costs also increased from USD $ 14.1 million, which is due to increased personnel costs and pre-commercial activities for Axpaxli.

Business and operational highlights

The company has made remarkable progress in its clinical studies for Axpaxli, an investigation of macular degeneration (AMD). The SOL-1 study has shown extraordinary retention rates, whereby the top line data is expected in the first quarter of 2026. The SOL-R study has also determined a strong registration, whereby a reduced target randomization is expected to accelerate the reading of the tests and the potential NDA submission time bar.

Ocular Therapeutix received a positive feedback from the FDA to draft a potential registering study against Axpaxli in non -proliferative diabetic retinopathy (NPDR). The company is actively planning the next steps in developing Axpaxli for NPDR and diabetic macular edema (DME).

Strategic initiatives and corporate developments

Ocular Therapeutix has implemented strategic regulatory updates to accelerate the SOL program and improve capital and operational efficiency. These updates could position Axpaxli for a 6 to 12-month dosage scheme for wet AMD and possibly enable an earlier NDA submission. As of March 31, 2025, the company will hold a strong cash balance of USD 349.7 million, which will probably support its planned expenses and capital requirements in 2028.

Perspective of management

Dr. Pravin U. Dugel, Executive Chairman, President and CEO of Ocular Therapeutix, emphasized the company's commitment to further develop the SOL Registration Program for Axpaxli in WET AMD. He lifted the strategic regulatory updates and positive FDA feedback as key factors in order to possibly achieve more sustainable therapy with better long-term results. Dr. Dügel was also optimistic about the strong capital position and the disciplined execution of the company, as this aims to become a leading retinal company.

Future prospects

Ocular Therapeutix assumes that net sales for the rest of 2025, which will increase to the expected increase in the number of units sold and the adjustments to the effects of MIPS, will increase. The company plans to provide further details on the development of Axpaxli for NPDR and DME at a later date.

SEC entry: Ocular Therapeutix, Inc. [ OCUL ] – 8 -k – May. 05, 2025